Richards F, Muss H B, Cooper R, White D R, Stuart J J, Howard V, Barnes P, Rhyne L, Spurr C L
Cancer. 1979 Jan;43(1):91-6. doi: 10.1002/1097-0142(197901)43:1<91::aid-cncr2820430114>3.0.co;2-r.
The combination of vincristine, methyl-CCNU, and methotrexate with or without MER-BCG achieved a 2% complete response (CR) and a 11% partial response (PR) with a median duration of 25-29 weeks in 124 evaluable patients with advanced adenocarcinoma of the colon and rectum. Responses were seen in previously untreated patients and in patients refractory to 5-fluorouracil. The median survival of these objective responders (CR + PR) was 57 weeks. The addition of MER-BCG did not appear to influence response rate or duration of survival and was accompanied by significant toxicity. Response was significantly correlated with performance status, sex, and disease free interval and survival with alkaline phosphatase and performance status. Patients with advanced colorectal carcinoma should be stratified according to these variables.
长春新碱、甲基环己亚硝脲和甲氨蝶呤联合或不联合MER -卡介苗，在124例可评估的晚期结肠直肠癌患者中，实现了2%的完全缓解（CR）和11%的部分缓解（PR），中位缓解持续时间为25 - 29周。在既往未治疗的患者以及对5 -氟尿嘧啶难治的患者中均观察到缓解。这些客观缓解者（CR + PR）的中位生存期为57周。添加MER -卡介苗似乎并未影响缓解率或生存期，且伴有显著毒性。缓解与体能状态、性别、无病间期显著相关，生存期与碱性磷酸酶和体能状态相关。晚期结直肠癌患者应根据这些变量进行分层。
